JP2022526823A5 - - Google Patents

Info

Publication number
JP2022526823A5
JP2022526823A5 JP2021559727A JP2021559727A JP2022526823A5 JP 2022526823 A5 JP2022526823 A5 JP 2022526823A5 JP 2021559727 A JP2021559727 A JP 2021559727A JP 2021559727 A JP2021559727 A JP 2021559727A JP 2022526823 A5 JP2022526823 A5 JP 2022526823A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
raav
composition according
itr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526823A (ja
JP7571044B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027764 external-priority patent/WO2020210698A1/en
Publication of JP2022526823A publication Critical patent/JP2022526823A/ja
Publication of JP2022526823A5 publication Critical patent/JP2022526823A5/ja
Priority to JP2024176952A priority Critical patent/JP7855045B2/ja
Application granted granted Critical
Publication of JP7571044B2 publication Critical patent/JP7571044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559727A 2019-04-10 2020-04-10 リソソーム障害のための遺伝子療法 Active JP7571044B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024176952A JP7855045B2 (ja) 2019-04-10 2024-10-09 リソソーム障害のための遺伝子療法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962831846P 2019-04-10 2019-04-10
US62/831,846 2019-04-10
US201962934450P 2019-11-12 2019-11-12
US62/934,450 2019-11-12
US201962954089P 2019-12-27 2019-12-27
US62/954,089 2019-12-27
US202062960471P 2020-01-13 2020-01-13
US62/960,471 2020-01-13
US202062988665P 2020-03-12 2020-03-12
US62/988,665 2020-03-12
PCT/US2020/027764 WO2020210698A1 (en) 2019-04-10 2020-04-10 Gene therapies for lysosomal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024176952A Division JP7855045B2 (ja) 2019-04-10 2024-10-09 リソソーム障害のための遺伝子療法

Publications (3)

Publication Number Publication Date
JP2022526823A JP2022526823A (ja) 2022-05-26
JP2022526823A5 true JP2022526823A5 (cg-RX-API-DMAC7.html) 2024-01-19
JP7571044B2 JP7571044B2 (ja) 2024-10-22

Family

ID=70554180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559727A Active JP7571044B2 (ja) 2019-04-10 2020-04-10 リソソーム障害のための遺伝子療法
JP2024176952A Active JP7855045B2 (ja) 2019-04-10 2024-10-09 リソソーム障害のための遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176952A Active JP7855045B2 (ja) 2019-04-10 2024-10-09 リソソーム障害のための遺伝子療法

Country Status (21)

Country Link
US (3) US11999974B2 (cg-RX-API-DMAC7.html)
EP (2) EP4707400A3 (cg-RX-API-DMAC7.html)
JP (2) JP7571044B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210150486A (cg-RX-API-DMAC7.html)
CN (1) CN114174324A (cg-RX-API-DMAC7.html)
AU (2) AU2020273182B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020183A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136004A1 (cg-RX-API-DMAC7.html)
DK (1) DK3953377T3 (cg-RX-API-DMAC7.html)
ES (1) ES3055985T3 (cg-RX-API-DMAC7.html)
FI (1) FI3953377T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251506T1 (cg-RX-API-DMAC7.html)
IL (1) IL286903A (cg-RX-API-DMAC7.html)
LT (1) LT3953377T (cg-RX-API-DMAC7.html)
MX (1) MX2021011958A (cg-RX-API-DMAC7.html)
PL (1) PL3953377T3 (cg-RX-API-DMAC7.html)
PT (1) PT3953377T (cg-RX-API-DMAC7.html)
RS (1) RS67476B1 (cg-RX-API-DMAC7.html)
SI (1) SI3953377T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600100T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020210698A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
EP3692158A4 (en) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
MX2020004005A (es) 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
HRP20251506T1 (hr) 2019-04-10 2026-01-02 Prevail Therapeutics, Inc. Genska terapija za lizosomske poremećaje
AU2021325891A1 (en) 2020-08-10 2023-04-06 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disorders
JP2025516136A (ja) 2022-04-19 2025-05-27 シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド 神経変性疾患の治療のための組み換えaavベクター
AU2023378899A1 (en) * 2022-11-13 2025-06-26 Alexion Pharma International Operations Limited Gene therapy for frontotemporal dementia
WO2024178352A2 (en) * 2023-02-24 2024-08-29 The Board Of Trustees Of The Leland Stanford Junior University Bmp synthase activators and inhibitors
WO2025251041A1 (en) * 2024-05-31 2025-12-04 Bluerock Therapeutics Lp METHODS AND COMPOSITIONS FOR TREATING PROGRANULIN DEFICIENCIES USING iPSC-DERIVED CELLS

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538119B2 (en) 1997-11-18 2003-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
ATE310096T1 (de) 2000-09-18 2005-12-15 Genzyme Corp Expressionsvektoren mit hybriden ubiquitin- promotoren
EP1463805B1 (en) * 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US20030133924A1 (en) 2001-12-21 2003-07-17 Novazyme Pharmaceuticals, Inc. Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
AU2003221733A1 (en) 2002-04-17 2003-11-03 University Of Florida Research Foundation, Inc. Improved raav vectors
WO2006036465A2 (en) 2004-09-03 2006-04-06 University Of Florida Compositions and methods for treating cystic fibrosis
EP2687223B2 (en) 2006-05-30 2024-11-20 Mayo Foundation For Medical Education And Research Detecting and treating dementia
JP5123936B2 (ja) * 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 認知症の検出および治療
HUE044182T2 (hu) 2006-06-07 2019-10-28 Genzyme Corp Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
ES2385679T3 (es) 2006-08-24 2012-07-30 Virovek, Inc. Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos
US20090176729A1 (en) 2007-12-14 2009-07-09 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
WO2009089635A1 (en) 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
US9265843B2 (en) 2008-03-27 2016-02-23 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
CA2818253A1 (en) 2010-11-16 2012-05-24 Denis G. Kay Method for increasing neprilysin expression and activity
HK1214521A1 (zh) 2012-11-05 2016-07-29 Genzyme Corporation 用於治療蛋白質病的組合物和方法
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
WO2016025523A1 (en) 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
EP3221456B1 (en) 2014-11-21 2021-09-22 University of Florida Research Foundation, Inc. Genome-modified recombinant adeno-associated virus vectors
CA2985235A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
HRP20231451T1 (hr) 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
CA3016314A1 (en) 2016-03-02 2017-09-08 Julianne REIDERS Therapy for frontotemporal dementia
WO2017178826A1 (en) * 2016-04-14 2017-10-19 The University Of Liverpool Diagnosing acute bacterial meningitis
CA3012699C (en) 2016-04-21 2023-11-21 Virovek, Inc Aav production in insect cells, methods and compositions therefor
MX2020004005A (es) 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
CN111542549A (zh) 2017-10-03 2020-08-14 普利维尔治疗公司 用于溶酶体障碍的基因疗法
EP3692158A4 (en) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
AU2018354195A1 (en) 2017-10-23 2020-06-04 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
EP4585229A3 (en) * 2017-11-08 2026-01-14 Novartis AG Means and method for preparing viral vectors and uses of same
BR112021020157A2 (pt) 2019-04-10 2021-12-14 Prevail Therapeutics Inc Terapias gênicas para transtornos lisossomais
HRP20251506T1 (hr) 2019-04-10 2026-01-02 Prevail Therapeutics, Inc. Genska terapija za lizosomske poremećaje
JP7664848B2 (ja) 2019-04-10 2025-04-18 プリベイル セラピューティクス,インコーポレーテッド リソソーム障害のための遺伝子療法
AU2021325891A1 (en) 2020-08-10 2023-04-06 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disorders

Similar Documents

Publication Publication Date Title
AU2023258449B2 (en) Acid-alpha glucosidase variants and uses thereof
US20240115734A1 (en) Recombinant aavs with improved tropism and specificity
US20220389399A1 (en) Acid-alpha glucosidase variants and uses thereof
JP2022526021A5 (cg-RX-API-DMAC7.html)
AU2020204679B2 (en) Gene therapy constructs for treating wilson disease
ES2970293T3 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas
JP2023537904A5 (cg-RX-API-DMAC7.html)
CN114667349A (zh) 用于调节腺相关病毒(aav)和aav受体(aavr)之间的相互作用以改变aav生物分布的方法和组合物
JP2023537903A5 (cg-RX-API-DMAC7.html)
CA3151442A1 (en) Sortilin receptor ligand based chimeric polypeptides and uses thereof
EP4127189A1 (en) Gene therapy for treating propionic acidemia
JP7788594B2 (ja) 乳児バッテン病の治療のための髄腔内および静脈内組合せ遺伝子療法
CN115605266A (zh) Dysferlin双载体的基因疗法
WO2021078834A1 (en) Chimeric acid-alpha glucosidase polypeptides and uses thereof
WO2025228321A1 (en) METHOD OF SEPARATING RECOMBINANT ADENO-ASSOCIATED VIRUS (rAAV) PARTICLES
EP4684808A1 (en) Plasmids, transgenes, vectors and medical uses comprising adamts13
WO2024161032A1 (en) Gene therapy vectors for use in parkinson's disease
HK40109828A (en) Acid-alpha glucosidase variants and uses thereof
WO2025090942A1 (en) Gene therapy for treatment of neurometabolic disease
CN121991975A (zh) 用于aav生产的衣壳蛋白编码核酸和杆状病毒载体